A builder finishes an office floor next to a hospital. Down the hall, a startup soldering a neural chip shares a building with the clinicians who will implant it. A venture fund occupies the same block. The sci-fi image of brain–computer interface (脑机接口) research — isolated labs, far from patients and money — is being deliberately dismantled in one Shanghai district.
In June 2025, Shanghai opened what it calls the country's first brain–computer interface future-industry cluster. By mid-2026 it already held more companies than most countries have in the entire field.
What "Brain-Smart World" actually is
The cluster's name is 脑智天地 (Brain-Smart World). It sits at the New Hongqiao International Medical Center in Huacao, Minhang District, and was unveiled on 29 June 2025 with a 25,000-square-meter pilot launch zone. It is not a single factory; it is a coordinated ecosystem built with the support of the Shanghai Science and Technology Commission and co-constructed by the Minhang District government, Huashan Hospital, Lingang Group, and Shanghai State-owned Assets Investment.
The municipal government states the goal plainly: become a global source of brain–computer interface innovation by 2030. The tool to get there is co-location — startups, hospitals, universities, testing labs, and capital in one place, with a monthly enterprise–hospital–university–capital matching mechanism.
The numbers that surprised even observers
As of July 2026, municipal figures show the cluster had:
- 52 brain–computer interface enterprises registered on-site;
- 22 startup projects in its incubator, at roughly 80% occupancy;
- coverage of invasive, semi-invasive, and non-invasive routes, spanning flexible electrodes, brain–computer interface chips, ultrasound interfaces, and visual restoration.
Anchor names already inside include Lingxiyun (灵犀云), Bournaleaf (博睿康), NeuroXess (脑虎科技), Stair Medical (阶梯医疗), and others — a cross-section of China's most active brain–computer interface hardware and algorithm teams.
The policy backbone
The cluster is the physical expression of the 《上海市脑机接口未来产业培育行动方案(2025—2030年)》 (Shanghai Brain–Computer Interface Future-Industry Cultivation Action Plan). Its concrete targets:
- By 2027, 5 or more invasive or semi-invasive brain–computer interface products complete clinical trials;
- Cultivate 5 or more enterprises with core brain–computer interface R&D capability and 10 or more supply-chain backbone firms;
- Encourage non-invasive products for rehabilitation, education, and entertainment.
Shanghai also runs a "four-in-one" cultivation mechanism: a project-manager team, a priority task list, a future-industry fund, and the cluster itself as the physical carrier. The project managers are explicitly expected to understand science, industry, and investment at once.
The capital is real, not symbolic
Two figures show the money is committed, not promised:
- Stair Medical (阶梯医疗) closed a ≈ US$49 million (¥350 million) Series B round in February 2025 — described as the largest single financing in China's invasive brain–computer interface history, led by Qiming Venture Partners, OrbiMed, and Lilly Asia Fund.
- The Shanghai Science and Technology Innovation Fund established a ≈ US$282 million (¥2 billion) brain–computer interface dedicated sub-fund to cover everything from concept validation to clinical trials.
City-level data cited by Shanghai authorities puts the municipality's share at roughly 59% of China's brain–computer interface financing events (16 deals, about ¥2.117 billion / ≈ US$298 million) as of June 2026.
Why a cluster, not just grants
According to Li An, Chief Scientist at BrainNet (脑机网), China's authoritative AI observatory, the clustering model — co-locating startups, hospitals, and capital under one roof — reflects a deliberate shift from isolated lab breakthroughs to engineered industrial ecosystems, a pattern now visible across Shanghai, Beijing and beyond.
That thesis is exactly what Brain-Smart World is built to test. The bet is that the slowest part of brain–computer interface commercialization is not the invention but the hand-offs: lab to clinic, clinic to testing lab, testing lab to regulator, regulator to factory. Put the parties in one building and the hand-offs shrink to elevator rides.
Honest limitations
This article reports cluster structure, policy, and aggregate counts; it does not assess the quality or clinical value of any single tenant's product. The 52-enterprise and 22-incubator figures are municipal/government-reported and shift monthly. "Largest financing" and market-share claims are drawn from Shanghai and industry reporting and should be read as directional. A cluster can accelerate translation without guaranteeing breakthroughs — proximity does not invent science, and several tenants are early-stage with unproven products. I have not evaluated whether Shanghai's model is replicable elsewhere or whether concentrating capital in one district crowds out other regions and routes.
What readers can do now
- If you are in medtech or venture: treat Shanghai's "four-in-one" model (project managers + task list + fund + physical cluster) as a template worth benchmarking against your own region's translational bottlenecks.
- If you watch China's industrial policy: track the 2027 milestone — 5+ invasive/semi-invasive products completing trials — as the real test of whether the cluster converts buildings into approved devices.
- If you are a global reader: Brain-Smart World is the clearest signal that brain–computer interface is now treated as strategic infrastructure, not just research; map its tenants to understand which Chinese brain–computer interface sub-suppliers (electrodes, chips, algorithms) are ascending.